About Gout Therapeutics
Gout is a form of arthritis which can be intensely painful and it is caused by having sodium urate crystals in joints. The approval of febuxostat, a non-purine-analogue inhibitor of xanthine oxidase, by the European Medicines Agency and the US Food and Drug Administration heralds a new era in the treatment of gout. Surging adoption of these biologics because of their ability to produce powerful anti-inflammatory action is likely to drive the market during the forecast period.
|High Growth Market
|Value (USD Billion)
The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Gout Therapeutics market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.
Regeneron Pharmaceuticals (United States), CymaBay Therapeutics (United States), LG Life Sciences (South Korea), Eisai Co., Ltd. (Japan), Antares Pharma (United States), Boehringer Ingelheim (Germany), AstraZeneca (United Kingdom), Takeda Pharmaceuticals (Japan), GlaxoSmithKline (United Kingdom), Eli Lilly (United States), Merck & Co. (United States) and Novartis (Switzerland) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Teijin Pharma (Japan), JW Pharmaceutical (South Korea), Vertex Pharmaceuticals (United States) and Astellas Pharma (Japan).
AMA Research has segmented the market of Global Gout Therapeutics market by Type (NSAIDs, Corticosteroids, Colchicine and Urate-Lowering Agents), Application (Hospitals and Clinics) and Region.
On the basis of geography, the market of Gout Therapeutics has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). North America region held largest market share in the year 2023. If we see Market by Diseases Type, the sub-segment i.e. Acute Gout will boost the Gout Therapeutics market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
Growing Focus on Regenerative Medicines by Key Players
Market Growth Drivers:
Increasing Adoption of Newer Therapies and Surging Number of Geriatric Population Across the World
Increased Drug Resistance and Side-Effects of the Prescribed Drugs
Lack of Awareness in Developing Economies
Increased in Incidence and Prevalence of Gout in Developed Economies and Increasing Adoption of Biologics
Market Leaders and their expansionary development strategies
In April 2022, Regeneron Pharmaceuticals has entered a definitive agreement to acquire all outstanding shares of clinical stage biopharmaceutical company Checkmate Pharmaceuticals The Checkmate takeover is anticipated to bolster Regeneron’s portfolio of varied and combinable immuno-oncology candidates.
In May 2019, Horizon Therapeutics plc announced the launch of Gout Lies, a data-driven campaign to reframe physician dialogue on the reality of living with gout and underscore findings of recent research that warrant a new view on how to properly manage the disease.
On 30 December 2020, The FDA has approved lesinurad (Zurampic) to be used in combination with allopurinol (Zyloprim) or febuxostat (Uloric) for the treatment of hyperuricemia associated with gout. Lesiunard is the first in a new class of drugs called selective uric acid reabsorption inhibitors (SURIs) to be approved in the United States.
Key Target Audience
Providers of Gout Therapeutics, Potential Investors, Market Research Firms, Regulatory Bodies, End-Users and Others
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.
Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.
The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.